The Performance of a Survival Nomogram and Albumin-Bilirubin Grade as Prognostic Tools in Advanced Hepatocellular Carcinoma Treated with FOLFOX4
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The albumin-bilirubin (ALBI) grade shows promise for predicting survival in advanced hepatocellular carcinoma (HCC) patients treated with FOLFOX4 chemotherapy. The survival nomogram requires further validation for this patient group.
Area Of Science
- Hepatobiliary Cancers
- Oncology
- Clinical Prognostics
Background
- Prognostic tools for advanced hepatocellular carcinoma (HCC) survival require validation in patients receiving FOLFOX4 chemotherapy.
- The EACH study's survival nomogram and albumin-bilirubin (ALBI) grade's predictive ability for this cohort are unassessed.
Purpose Of The Study
- To evaluate the prognostic value of the EACH study survival nomogram and ALBI grade in advanced HCC patients treated with FOLFOX4.
- To determine the clinical utility of these tools for risk stratification and survival prediction.
Main Methods
- Retrospective analysis of 76 advanced HCC patients treated with FOLFOX4.
- Assessment of survival nomogram and ALBI grade for each patient.
- Calculation of Area Under the Receiver Operating Curve (AUROC) and Harrell's C-index.
Main Results
- The survival nomogram showed limited predictive accuracy (AUROC 0.621, C-index 0.589) across risk groups.
- ALBI grade demonstrated significant prognostic value (p=0.00024) with higher AUROC (0.663) and C-index (0.663).
- Median overall survival varied significantly by ALBI grade (Grade 1: 9.82 months, Grade 2: 6.83 months, Grade 3: 1.58 months).
Conclusions
- ALBI grade is a potential prognostic tool for advanced HCC patients receiving FOLFOX4.
- The survival nomogram requires further validation due to insufficient discrimination.
- FOLFOX4 may be considered for ALBI grade 1 patients ineligible for other therapies; larger prospective studies are needed.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...